Direct renin inhibition exerts an anti-hypertrophic effect associated with improved mitochondrial function in post-infarction heart failure in diabetic rats

Cellular Physiology and Biochemistry

Volumn 29, Issue 5-6, 2012, Pages 841-850

  Rats, Diabetic ^a   Parodi Rullan, Rebecca ^a   Barreto Torres, Giselle ^a   Ruiz, Louis ^a   Casasnovas, José ^a   Javadov, Sabzali ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Heart failure; Mitochondria; Post myocardial infarction; Renin angiotensin system

Indexed keywords

ALISKIREN; CYCLOPHILIN D; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; SIRTUIN 3; STREPTOZOCIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING RATE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIABETES MELLITUS; DRESSLER SYNDROME; HEART EJECTION FRACTION; HEART FAILURE; HEART OUTPUT; MALE; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; RESPIRATION CONTROL; SHAM PROCEDURE; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

EID: 84861415338     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000178526     Document Type: Article

References (39)

1. Wollert KC, Drexler H: The reninangiotensin system and experimental heart failure. Cardiovasc Res 1999;43:838-849. (Pubitemid 29413183)
2. nd : Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 2009;6:283-291.
3. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H: Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin ii type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-2282. (Pubitemid 24142808)
4. Wollert KC, Studer R, von Bulow B, Drexler H: Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90:2457-2467. (Pubitemid 24354334)
5. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Jan Danser AH, Schultheiss HP, Tschope C: Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008;52:1068-1075.
6. Singh VP, Le B, Khode R, Baker KM, Kumar R: Intracellular angiotensin ii production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008;57:3297-3306.
7. Stanley WC, Chandler MP: Energy metabolism in the normal and failing heart: Potential for therapeutic interventions. Heart Fail Rev 2002;7:115-130. (Pubitemid 34624800)
8. Marin-Garcia J, Goldenthal MJ: Mitochondrial centrality in heart failure. Heart Fail Rev 2008;13:137-150.
9. Sheeran FL, Pepe S: Energy deficiency in the failing heart: Linking increased reactive oxygen species and disruption of oxidative phosphorylation rate. Biochim Biophys Acta 2006;1757:543-552.
10. Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, Utsumi H, Hamasaki N, Takeshita A: Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001;88:529-535. (Pubitemid 32240917)
11. Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, Colucci WS, Sawyer DB: Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail 2005;11:473-480.
12. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM: Pivotal role of a gp91 (phox) - containing nadph oxidase in angiotensin ii-induced cardiac hypertrophy in mice. Circulation 2002;105:293-296. (Pubitemid 34106175)
13. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM: Contrasting roles of nadph oxidase isoforms in pressure-overload versus angiotensin ii-induced cardiac hypertrophy. Circ Res 2003;93:802-805.
14. Whaley-Connell A, Habibi J, Cooper SA, Demarco VG, Hayden MR, Stump CS, Link D, Ferrario CM, Sowers JR: Effect of renin inhibition and at1r blockade on myocardial remodeling in the transgenic ren2 rat. Am J Physiol Endocrinol Metab 2008;295:E103-109.
15. Javadov S, Huang C, Kirshenbaum L, Karmazyn M: NHE-1 inhibition improves impaired mitochondrial permeability transition and respiratory function during postinfarction remodelling in the rat. J Mol Cell Cardiol 2005;38:135-143. (Pubitemid 40038660)
16. Srere PA: Citrate synthase. Methods Enzymol 1969;13:3-11.
17. Javadov S, Rajapurohitam V, Kilic A, Zeidan A, Choi A, Karmazyn M: Antihypertrophic effect of NHE-1 inhibition involves GSK-3beta-dependent attenuation of mitochondrial dysfunction. J Mol Cell Cardiol 2009;46:998-1007.
18. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using realtime quantitative pcr and the 2 (-delta delta c (t)) method. Methods 2001;25:402-408. (Pubitemid 34164012)
19. Shulga N, Wilson-Smith R, Pastorino JG: Sirtuin-3 deacetylation of cyclophilin d induces dissociation of hexokinase ii from the mitochondria. J Cell Sci 2010;123:894-902.
20. Shulga N, Pastorino JG: Ethanol sensitizes mitochondria to the permeability transition by inhibiting deacetylation of cyclophilin-d mediated by sirtuin-3. J Cell Sci 2010;123:4117-4127.
21. Guarente L: Sirtuins as potential targets for metabolic syndrome. Nature 2006;444:868-874. (Pubitemid 46024994)
22. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D, Murphy A, Yang Y, Chen Y, Hirschey MD, Bronson RT, Haigis M, Guarente LP, Farese RV, Jr., Weissman S, Verdin E, Schwer B: Mammalian sir2 homolog sirt3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 2007;27:8807-8814.
23. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G: The renin angiotensin system in the development of cardiovascular disease: Role of aliskiren in risk reduction. Vasc Health Risk Manag 2008;4:971-981.
24. Ismail H, Mitchell R, McFarlane SI, Makaryus AN: Pleiotropic effects of inhibitors of the raas in the diabetic population: Above and beyond blood pressure lowering. Curr Diab Rep 2010;10:32-36.
25. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M: Overexpression of angiotensin ii type i receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 2000;97:931-936. (Pubitemid 30070412)
26. Dostal DE, Baker KM: The cardiac reninangiotensin system: Conceptual, or a regulator of cardiac function? Circ Res 1999;85:643-650.
27. Miyazaki M, Takai S: Tissue angiotensin ii generating system by angiotensinconverting enzyme and chymase. J Pharmacol Sci 2006;100:391-397. (Pubitemid 44609530)
28. Singh VP, Le B, Bhat VB, Baker KM, Kumar R: High-glucose-induced regulation of intracellular ang ii synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 2007;293:H939-948. (Pubitemid 47254192)
29. Krop M, Danser AH: Circulating versus tissue renin-angiotensin system: On the origin of (pro) renin. Curr Hypertens Rep 2008;10:112-118.
30. Connelly KA, Advani A, Kim S, Advani SL, Zhang M, White KE, Kim YM, Parker C, Thai K, Krum H, Kelly DJ, Gilbert RE: The cardiac (pro) renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. J Hypertens 2011;29:1175-1184.
31. Nguyen G, Muller DN: The biology of the (pro) renin receptor. J Am Soc Nephrol 2010;21:18-23.
32. Ye Y, Qian J, Castillo AC, Perez-Polo JR, Birnbaum Y: Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther 2011;25:505-515.
33. Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, Nagai R, Sata M: Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. Hypertens Res 2012;35:62-69.
34. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA: Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011;32:1227-1234.
35. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T: A role for the mitochondrial deacetylase sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008;105:14447-14452.
36. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV Jr, Alt FW, Kahn CR, Verdin E: Sirt3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010:464:121-125.
37. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair DA: Regulation of the mptp by sirt3-mediated deacetylation of cypd at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) 2010;2:914-923.
38. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP: Sirt3 blocks the cardiac hypertrophic response by augmenting foxo3adependent antioxidant defense mechanisms in mice. J Clin Invest 2009;119:2758-2771.
39. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O'Rourke B, Walston JD: Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci USA 2011;108:14849-14854.